Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Clinical Trials Experience-9)

In this article, we will discuss Olaparib (Clinical Trials Experience-9). So, let’s get started.

The median duration of study treatment was 8.2 months in patients
who received Olaparib and 3.4 months in patients who received chemotherapy. Dose interruptions due to
an adverse reaction of any grade occurred in 35% of patients receiving Olaparib and 28% of those
receiving chemotherapy; dose reductions due to an adverse reaction occurred in 25% of Olaparib patients
and 31% of chemotherapy patients. Discontinuation occurred in 5% of Olaparib patients and 8% in
chemotherapy patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.